文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病患者接受异基因移植时诊断期与缓解期IDH1和IDH2突变检测的影响

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
PubMed 文献 · Blood Adv · 2023-01-01

该研究分析了292例接受异基因造血干细胞移植的急性髓系白血病患者,评估诊断时和移植时IDH突变状态作为可测量残留病标志物的价值。约四分之一患者诊断时存在IDH突变,诊断时IDH突变对移植巩固后的预后无显著影响;但移植时IDH1 R132和IDH2 R172突变阳性与复发风险增加相关,而IDH2 R140突变无此关联。

要点

  • 诊断时IDH突变在接受移植巩固的AML患者中无显著预后影响。
  • 移植时IDH1 R132和IDH2 R172突变阳性与复发风险增加相关。
  • IDH2 R140突变在移植时清除率较低,行为类似克隆性造血相关异常。

核心结论

  • 诊断时IDH突变在接受异基因造血干细胞移植巩固的AML患者中无显著预后影响。
  • 移植时IDH1 R132和IDH2 R172突变阳性与复发风险增加相关,而IDH2 R140突变无此关联。
  • IDH2 R140突变在形态学缓解时移植时清除率较低,行为更似克隆性造血相关异常;IDH1 R132和IDH2 R172具有AML疾病特异性特征。

研究设计与样本

  • 该研究为对292例接受异基因造血干细胞移植的AML患者进行的大型分析,患者移植时处于完全缓解(CR)或完全缓解伴外周血细胞不完全恢复(CRi)。
  • 研究评估了诊断时和移植时的IDH突变状态,作为可测量残留病(MRD)的潜在标志物。

主要发现

  • 约四分之一患者诊断时存在IDH突变。
  • 诊断时IDH突变在接受移植巩固的AML患者中无显著预后影响。
  • 移植时IDH1 R132和IDH2 R172突变MRD阳性与复发风险增加相关,而IDH2 R140突变无此关联。
  • 诊断时IDH2 R140变异等位基因频率(VAF)较高,聚集在50%左右,且形态学缓解时移植时突变清除率远低于IDH1 R132和IDH2 R172。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatic mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are common in acute myeloid leukemia (AML). The prognostic impact of the presence of IDH mutations may be influenced by the comutational status, the specific location of the mutation (ie, IDH1 R132, IDH2 R140, and IDH2 R172) at diagnosis, and the dynamics of the mutation burden during disease course. Even though many patients with IDH-mutated AML are consolidated by hematopoietic stem cell transplantation (HSCT), the underlying biology and prognostic consequences remain largely unknown. Here, we present a large analysis of 292 patients with AML who received HSCT in complete remission (CR) or CR with incomplete peripheral recovery (CRi), in which we assessed the IDH mutation status at diagnosis and HSCT as a potential marker for measurable residual disease (MRD). About a quarter of all patients were IDH-mutated at diagnosis. The diagnostic presence of IDH mutations in AML did not have a significant prognostic impact when consolidated with HSCT. However, IDH1 R132 and IDH2 R172 MRD positivity in remission at HSCT associated with an increased risk of relapse, while IDH2 R140 mutations did not. The IDH2 R140 variant allele frequency (VAF) at diagnosis was higher, clustering around 50%, and the mutation clearance at HSCT in morphologic remission was much lower compared with IDH1 R132 and IDH2 R172. In our cohort, IDH2 R140 mutations behaved more like a clonal hematopoiesis-related aberration, while IDH1 R132 and IDH2 R172 harbored AML disease-specific features.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bill M, Jentzsch M, Bischof L, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2023. PMID: 35381077. doi:10.1182/bloodadvances.2021005789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。